The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 41 | 32.8x | 20.1x | Near average | |
Growth | 56 | 31.9% | 5.6% | Near average | |
Quality | 82 | 78.8% | 7.6% | Above average | |
Safety | 78 | -1.2x | 0.4x | Above average | |
Capital Return | 51 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Insulet Corporation is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Insulet Corporation shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Insulet stock has seen a 2.23% decline in its average price target over the past 30 days, with the consensus dropping from $232.18 to $227, despite the number of analysts remaining steady at 9. This downward adjustment reflects caution in short-term expectations, even as major institutions such as Goldman Sachs and Benchmark maintain a 'Buy' rating, indicating a gap between optimistic valuation and current price reality.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.